| London Stock Exchange: INS
Instem Plc provides laboratory data and information management solutions for drug safety studies. The company offers early drug development software solutions. Its solutions include Provantis, a Windows-based system for organizations and universities engaged in non-clinical evaluation studies in the areas of clinical pathology, formulation, general toxicology, pathology, protocol preparation, reporting, reproductive toxicology, tables and statistics, and data import; Submit SEND solution for collecting, organizing, and exchanging research data; and toxicology resource planning, centrus, translational informatics, formulation, information management, and regulatory compliance. The company also provides a range of business intelligence, planning, workflow management, dosage formulation, document management, and report compilation applications; project management, installation services, validation, requirements review and GAP analysis, risk assessment and mitigation, database migration validation, on-site installation and execution of the validation solution, QA verification, data management, training, solution development, remote systems, and client support services; and software-as-a-service solution. It serves pharmaceutical, contract research, chemical, agrochemical, academia, and bio-tech companies, as well as government research institutes and consultants. The company also provides software-as-a-service solutions. Instem has strategic partnerships with Microsoft, Oracle, CTCLS, Datapipe, SAS, Business Objects, and Asta Development. Instem was founded in 1969 by David Gare and is headquartered in Stone, the United Kingdom.